查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
克隆和诱变市场-全球行业规模,趋势,机会和预测,2018-2028 年,按基因型,按产品类型,按技术,按应用,按最终用户,按地区,按竞争
市场调查报告书
商品编码
1255234

克隆和诱变市场-全球行业规模,趋势,机会和预测,2018-2028 年,按基因型,按产品类型,按技术,按应用,按最终用户,按地区,按竞争

Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Gene Type, By Product Type, By Technique, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 119 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球克隆和诱变市场预计在预测期内将出现显着增长。

这可能是由于克隆方法在各种遗传应用中的扩展，例如生殖克隆和基因克隆。此外，克隆和诱变市场受到各种需要克隆和诱变试剂盒的新产品发布以及政府机构投资于干细胞研究以在世界各个地区开发新疗法和疗法的推动。对克隆和诱变的需求已经显着增加此外，全球越来越多的易患各种疾病和肥胖的老年人口也有望进一步增加对克隆和诱变的需求，推动市场增长到 2028 年。此外，人们越来越意识到基因治疗和诊断的好处，以及增加治疗慢性病的医疗保健支出，预计将在预测期内进一步推动克隆和诱变市场。到 2022 年，估计美国将有 66,470 人（48,520 名男性和 17,950 名女性）被诊断出患有头颈癌。

癌症和其他慢性病研发活动的增加将推动市场增长

为开发癌症疗法和其他罕见疾病而增加的克隆和诱变研发预计将在预测期内推动市场利润丰厚的增长。政府机构正在寻求能为他们带来更高回报的发达基础设施。可用于癌症治疗的各种创新和伦理上可接受的治疗方式，以及不断增加的新产品开发，预计将在未来几年推动市场增长。2020 年 5 月，Takara Bio 宣布与 AGC Biologics 合作，两家公司的业务将合作开发针对 COVID-19 的预防性 DNA 疫苗，AGC Biologics 将为该疫苗生产质粒 DNA 中间体。AGC Biologics 已决定製造针对 COVID-19 的预防性 DNA 疫苗，以应对越来越多的由欧盟委员会和日本医学研究与开发机构等公共基金资助的研究。到 2020 年，估计美国将诊断出 276,480 例浸润性乳腺癌新病例和 48,530 例原位乳腺癌新病例。越来越多的基因克隆以合成抗生素、激素、维生素等以治疗囊性纤维化等正在推动市场的增长。

政府机构增加投资推动市场增长

预计将创造市场有利增长的关键因素包括治疗技术的进步，以及基因合成和克隆服务的有利融资场景，其次是研究、亚克隆服务以及市场协同效应的增强等等。预计在预测期内，对基因治疗的需求不断增加，新型和先进的 DNA 克隆技术的采用不断增加，预计将产生利润丰厚的市场增长。

近期发展状况

  • 2021 年 1 月，Codex DNA 与Pfizer签订了一项早期研究合作和许可协议，根据该协议，Pfizer将能够使用 CodexDNA 的新型□促 DNA 合成技术来研发基于 mRNA 的疫苗和生物治疗药物。负责进一步开发的技术。
  • 2020年5月，GenScript刚刚推出GMP单炼和双链DNA服务，支持基因和细胞疗法的发展。该公告强调了 GenScript 在整个 IND 和临床阶段支持非病毒细胞疗法开发的承诺。

可定制

鑑于市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以定制为：

关于我们

  • 对其他市场参与者（最多 5 个）的详细分析和概况分析。

目录

第一章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年
    • 主要市场细分

第二章研究方法论

  • 研究目标
  • 基线调查法
  • 重点行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第三章执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势概述

第四章VOC（客户之声）

第五章克隆和诱变的全球市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型（标准型/复杂型）
    • 按产品类型（克隆试剂盒/致突变试剂盒）
    • 按方法（Topo PCR 克隆、Blunt End 克隆、无缝克隆、定点诱变等）
    • 按应用（基因合成、基因表达、基因治疗、疫苗研究等）
    • 按最终用户（製药/生物技术公司、学术/研究机构等）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按地区

第六章北美克隆诱变市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按国家
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

七、欧洲克隆诱变市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

八、亚太克隆诱变市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按国家
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第九章南美克隆诱变市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按国家
  • 南美洲：：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章中东和非洲克隆和诱变市场展望

  • 市场规模/预测
    • 按金额
  • 市场份额及预测
    • 按基因型
    • 按产品类型
    • 通过技术
    • 按申请
    • 按最终用户
    • 按国家
  • MEA：国家分析
    • 南非
    • 沙特阿拉伯
    • 阿联酋

第十一章市场动态

  • 促进者
  • 任务

第十二章市场趋势与发展

  • 最近的发展
  • 嘛
  • 产品展示

第13章竞争格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Agilent Technologies, Inc.
    • Eurofins Scientific SE
    • Sartorius AG
    • Collecta, Inc.
    • Codex DNA Inc.
    • Lonza Group AG
    • Charles River Laboratories International, Inc.
    • TransGene Biotech Co. Ltd.
    • Takara Bio, Inc.
    • Thermo Fisher Scientific Inc.

第十四章战略建议

简介目录
Product Code: 14421

The Global Cloning & Mutagenesis Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing cloning approaches in different genetic applications like reproductive cloning and genetic cloning. Additionally, various new product launches in the cloning and mutagenesis market, which will demand cloning and mutagenesis kits, along with government organizations investing in stem cell research for the development of new treatments and therapy, have significantly increased the demand for cloning and mutagenesis across different parts of the globe. Additionally, the growing geriatric population across the globe, which is susceptible to different kinds of diseases and obesity, is further expected to increase the demand for cloning and mutagenesis, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on chronic disease treatment across the globe, are further expected to support the cloning and mutagenesis market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.

Increasing Research and Development Activities in Cancer and Other Chronic Disorders Fueling the Market Growth

Increasing research and development regarding cloning and mutagenesis for the development of cancer therapies and other rare disorders is expected to create lucrative growth in the market during the forecast period. Government organizations are focusing on developed infrastructure with higher profits. Different types of innovative and ethically accepted therapies available for cancer therapy, along with the increasing development of new products, are expected to boost market growth over the years. In May 2020, Takara Bio announced a collaboration with AGC Biologics, and their businesses would collaborate on a prophylactic DNA vaccine against COVID-19 with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. . as public-funded research is getting a boost from bodies such as the European Commission and the Japan Agency for Medical Research and Development. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer. The increasing cloning of genes for the synthesis of antibiotics, hormones, and vitamins, among others, for the treatment of issues such as cystic fibrosis is propelling the market growth.

Increasing Investment by Government Organizations is Driving the Market Growth

Important factors which are expected to create lucrative growth in the market include a favorable funding scenario for gene synthesis and cloning services, along with technological advancement in the treatment, followed by research, subcloning services, and rising synergistic activities in the market. Increasing demand for gene therapy and growing adoption of novel and advanced DNA cloning technologies are expected to create a lucrative growth of the market during the forecast period.

Market Segmentation

Global cloning & mutagenesis market can be segmented by gene type, product type, technique, application, end-user, and by region. Based on gene type, the market can be divided into Standard and Complex. Based on product type, the market can be divided into Cloning Kits and Mutagenesis Kits. Based on technique, the market can be segmented into Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, and Others. Based on application, the market can be segmented into Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, and Others. Based on the end user, the market can be differentiated into Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America.

Market Players

Agilent Technologies, Inc., Eurofins Scientific SE, Sartorius AG, Collecta, Inc., Codex DNA Inc., Lonza Group AG, Charles River Laboratories International, Inc., TransGene Biotech Co. Ltd., Takara Bio, Inc., Thermo Fisher Scientific Inc. are some of the leading players operating in the Global Cloning & Mutagenesis Market.

Recent Developments

  • In Jan 2021, Codex DNA and Pfizer signed an early access collaboration and licensing agreement, which will allow Pfizer to use CodexDNA's novel enzymatic DNA synthesis technology in its research and development of mRNA-based vaccines and biotherapies and it will be responsible for further developing the technology.
  • In May 2020, GenScript just launched a GMP single-strand and double-strand DNA service to aid in the growth of gene and cell therapies. The announcement highlights GenScript's commitment to assisting entire non-viral cell therapy development through the IND-enabling and clinical stages.

Report Scope

In this report, global cloning & mutagenesis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

  • Standard
  • Complex

Cloning & Mutagenesis Market, By Product Type:

  • Cloning Kits
  • Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

  • Topo PCR Cloning
  • Blunt End Cloning
  • Seamless Cloning
  • Site-Directed Mutagenesis
  • Others

Cloning & Mutagenesis Market, By Application:

  • Gene Synthesis
  • Gene Expression
  • Gene Therapy
  • Vaccine Research
  • Others

Cloning & Mutagenesis Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Others

Cloning & Mutagenesis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cloning & Mutagenesis Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Gene Type (Standard v/s Complex)
    • 5.2.2. By Product Type (Cloning Kits v/s Mutagenesis Kits)
    • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
    • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Gene Type
    • 5.3.2. By Product Type
    • 5.3.3. By Technique
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Cloning & Mutagenesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Gene Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technique
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cloning & Mutagenesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Gene Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Technique
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Gene Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Technique
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Gene Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Technique
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Gene Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technique
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cloning & Mutagenesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Gene Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Germany Cloning & Mutagenesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Gene Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Gene Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Gene Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Technique
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Gene Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Technique
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Cloning & Mutagenesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Gene Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technique
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cloning & Mutagenesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Gene Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Cloning & Mutagenesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Gene Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Gene Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Gene Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Gene Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Cloning & Mutagenesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Gene Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technique
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cloning & Mutagenesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Gene Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Cloning & Mutagenesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Gene Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Cloning & Mutagenesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Gene Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Cloning & Mutagenesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Gene Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technique
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cloning & Mutagenesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Gene Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Cloning & Mutagenesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Gene Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Cloning & Mutagenesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Gene Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Agilent Technologies, Inc.
    • 13.6.2. Eurofins Scientific SE
    • 13.6.3. Sartorius AG
    • 13.6.4. Collecta, Inc.
    • 13.6.5. Codex DNA Inc.
    • 13.6.6. Lonza Group AG
    • 13.6.7. Charles River Laboratories International, Inc.
    • 13.6.8. TransGene Biotech Co. Ltd.
    • 13.6.9. Takara Bio, Inc.
    • 13.6.10. Thermo Fisher Scientific Inc.

14. Strategic Recommendations